ID 119010023
Alternative Names: ID-119010023Latest Information Update: 22 Jan 2023
At a glance
- Originator Ildong Pharmaceutical
- Class Small molecules
- Mechanism of Action Nitric oxide donors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Pulmonary arterial hypertension
Most Recent Events
- 13 Dec 2022 Discontinued - Preclinical for Adult respiratory distress syndrome in South Korea (unspecified route) (Ildong Pharmaceutical pipeline, November 2022)
- 13 Dec 2022 Discontinued - Preclinical for Pulmonary arterial hypertension in South Korea (unspecified route) (Ildong Pharmaceutical pipeline, November 2022)
- 26 May 2022 Preclinical trials in Pulmonary arterial hypertension in South Korea (unspecified route) (Ildong Pharmaceutical pipeline, May 2022)